The aim of this prospective study is to assess the efficacy of autologous Platelet Rich Plasma combined with Hyaluronic Acid prepared with RegenKit-BCT HA Cellular Matrix on skin rejuvenation. Thirty-one patients were included and received three PRP-AH injection sessions 4 weeks apart into the cheeks. The outcomes were assessed at baseline, 1, 3 and 6 months after the last injection session. Safety was assessed by reported adverse event analysis.

Inclusion Criteria:

• Patients aged over 40 years with chronological aging
• Completed informed consent form

Exclusion Criteria:

• Pregnancy or breastfeeding
• Patients younger than 40 years
• Use of product or treatment aimed to improve skin rejuvenation over the last six months before study start,
• patients with known hypersensitivity to HA,
• patients with eczema flare-up,
• patients with active skin disorder infection including herpes virus infection, active hepatitis or human infection virus infection.
• Dermatological diseases affecting the face
• Auto-immune disease such as Hashimoto, rheumatoid arthritis.
• Malignancy with or without metastatic disease
• Chemotherapy
• Anticoagulant therapy